Why the study?
Does mianserin or amitriptyline improve depression scores compared to placebo in outpatients with major depression?
Does mianserin or amitriptyline improve depression scores compared to placebo in outpatients with major depression?
Mianserin is an effective and well-tolerated treatment for major depression, with efficacy comparable to amitriptyline but potentially faster onset and fewer anticholinergic side effects like dry mouth.
Answers are grounded in this paper and cite their sources.
Supports mianserin for faster onset in major depression; confirms RCT efficacy of both agents versus placebo in outpatients.
We report on the results of a study comparing mianserin with amitriptyline and placebo, in outpatients with major depression (DSM-III 296.2 or 296.3). One hundred and forty-nine patients were randomized to mianserin (n = 50), amitriptyline (n = 50) or placebo (n = 49). Medication was taken in a nightly (qhs) dose. During Week 1, the maximum dose was 60 mg mianserin, 120 mg amitriptyline or two placebo capsules. Beginning at Day 7 (through Day 42) maximum dosages were 150 mg mianserin, 300 mg amitriptyline or five placebo capsules. At multiple weeks and endpoint, statistically significant reductions in the Hamilton Depression Scale (HAM-D) 17- and 21-item scores were recorded for both active drugs compared with placebo. Positive results with the HAM-D were corroborated by other measures of efficacy. There were no statistically significant differences between mianserin and amitriptyline in terms of efficacy; however, the results do suggest a more rapid therapeutic response for mianserin compared with amitriptyline, in terms of percentage of patients showing > or = 50% improvement at Weeks 2 (30% vs 23%) and 4 (61% vs 44%). The most common adverse experiences were somnolence (amitriptyline and mianserin 60%, placebo 31%) and dry mouth (amitriptyline 76%, mianserin 30% and placebo 20%). Our results indicate that mianserin is clearly superior to placebo, compares favorably with amitriptyline, and is a safe, well-tolerated, effective medication in the treatment of depressed outpatients.
No takes yet. Share an insight, caveat, or question.
Wilcox et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: